The invention provides bupropion analogue compounds capable of inhibiting thereuptake of one or moremonoamines. The compounds may selectively bind to one or more monoaminetransporters, including those for dopamine,nore-pinephrine, and serotonin. Such compounds may be used to treat conditionsthat are responsive to inhibition of the reuptake ofmonoamines, including addiction, depression, and obesity.